Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to make End-of-Life conversations easier for cancer patients

NCT ID NCT04515810

Symptom relief Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study tests a mobile app called PACT that helps people with advanced cancer talk about and plan the care they would want if they couldn't speak for themselves. The app involves patients and their loved ones in these discussions. Researchers want to see if the app is easy to use and if it helps patients take action on advance care planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Planning Advance Care Together (PACT) mobile app
What this could lead to
If successful, this app could help more cancer patients discuss and document their care wishes, reducing stress for families and ensuring patients' preferences are respected.
What could go wrong
This is an early feasibility study with 400 participants, so it may not prove the app improves actual care outcomes. The app requires internet access, which may limit use for some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PATIENT: Diagnosis of poor prognosis advanced cancer defined as locally advanced or metastatic solid cancer and/or disease progression following at least first line systemic therapy and/or relapsed or refractory hematologic cancer. * PATIENT: Have internet access through a computer or a mobile device; the principal investigator (PI) will ensure that those who have access to a computer or mobile device have access to a computer or mobile device with internet access to ensure they can complete study procedures. * PATIENT: The ability to provide informed consent. * PATIENT: Identification of a loved support person if one is available; patients who are unable to identify a support person willing to participate with them will be allowed to continue in the study on their own. * PATIENT: 18 years of age or older. * SUPPORT PERSON: The person (family member or friend) whom the patient indicates being a support person. * SUPPORT PERSON: English speaking. * SUPPORT PERSON: 18 years of age or older and able to provide informed consent. * PROVIDER: Current clinical practice and/or research with advanced cancer patients. * PROVIDER: A history of 3+ years working with advanced cancer patients. * PROVIDER: 18 years of age or older. Providers across disciplines (e.g., social work, oncology) will be enrolled. Exclusion Criteria: * PATIENT: Not fluent in English. * PATIENT: Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \>= 6) to be delivered by trained study research staff during screening. * PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer). * PATIENT: Currently receiving hospice at the time of enrollment. * PATIENT: Children and young adults under age 18.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced malignant solid neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Death hematopoietic and lymphoid system neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis refractory hematologic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced malignant solid neoplasm Malignant solid neoplasm Metastatic malignant solid neoplasm Recurrent hematologic malignancy Refractory hematologic malignancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

  • Mount Sinai Hospital

    ACTIVE_NOT_RECRUITING

    New York, New York, 10029, United States

  • NYP/Weill Cornell Medical Center

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

  • Northwell Health

    NOT_YET_RECRUITING

    Manhasset, New York, 11030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.